The author’s experience of 20 years as director of the medical genetic services program in Cuba is presented. The setting of the infrastructure for equipment and the training of personnel for the medical genetic program began in 1981 in the city of Havana, and was progressively extended to cover the whole country in 1988. Between 1982 and 2002, 2.8 million pregnant women were tested for sickle cell carrier status, 96,000 carriers and 4,786 couples at risk were detected and offered genetic counseling and prenatal diagnosis. In the same period, the combination of maternal serum α-fetoprotein screening and fetal ultrasound led to the prenatal diagnosis of anomalies in several thousand fetuses. The accessibility to legal abortion, and the autonomous decisions by the majority of couples to terminate abnormal pregnancies reduced the prevalence of neural tube defects and sickle cell disease at birth by 90 and 65%, respectively, by 2002. In the span of approximately 20 years, 22,690 pregnant women at risk received prenatal chromosomal diagnosis. Newborn screening for phenylketonuria and congenital hypothyroidism was established. Genetic counseling was offered to every detected person or family at risk for genetic conditions. The network of medical genetic services established in the country received a very positive acceptance by the population. A very successful connection with the primary health care level was established.

Keywords:
Congenital anomalies, Cuba, Genetic counseling, Genetic screening, Genetic services, Neural tube defects, Prenatal diagnosis, Sickle cell disorders
1.
Heredero L: Comprehensive national genetic program in a developing country – Cuba. Birth Defects Orig Artic Ser 1992;28,3:52–57.
2.
Heredero L: Los servicios de genética médica en Cuba. Braz J Genet 1997;20,1:47–53.
3.
Galjaard H: Genetic technology in health care. Int J Technol Assess Health Care 1994;10:527–545.
4.
Penchaszadeh V: Preventing congenital anomalies in developing countries. Community Genet 2002;5:61–69.
5.
Sickle Cell Anemia in Cuba and its Prevention. Rev Cub Ped 1974;46:2–3.
6.
Heredero L, Granda H, Suarez J, Altland K: An economic high speed electrophoretic screening system for hemoglobin S and other proteins. Humangenetik 1974;21:167–177.
7.
Modell B, Kuliev A: The history of community genetics: The contribution of the haemoglobin disorders. Community Genet 1998;1:3–11.
8.
Korner H, Rodríguez L, Fernández JL, Schulze M, Horn A, Heredero L, Witkowski R, Tinschert S, Oliva JA, Sommer D, Zwahr Ch, Prenzlau P, Cobet G, Gunter H: Maternal serum alpha-fetoprotein screening for neural tube defects and other disorders using an ultramicro-ELISA. Hum Genet 1986;73:60–63.
9.
Rodríguez L, Heredero L, Padrón L: Incidencia de los defectos de cierre del tubo neural. Rev Cub Ped 1979;51:125–131.
10.
Granda H, Gispert S, Dorticós A, Martin M, Cuadras Y, Calvo M, Martinez G, Zayas MA, Oliva JA, Heredero L: Cuban programme for prevention of sickle cell disease. Lancet 1991;337:152–153.
11.
Granda H, Gispert S, Martínez G, Gómez M, Ferreira R, Collazo T, Magarino C, Heredero L: Results from a reference laboratory for prenatal diagnosis of sickle cell disorders in Cuba. Prenat Diagn 1994;14:659–662.
12.
Dorticós A, Martin M, Echevarria P, Robaina M, Rodríguez M, Moras F, Granda H: Reproductive behaviour of couples at risk for sickle cell disease in Cuba: A follow-up study. Prenat Diagn 1997;17:737–742.
13.
García T, Nordet I, Machín S, González A, Muñiz A, Martínez G, Wade M, Svarch E: Aportes al estudio de la drepanocitosis. Análisis clínico y hematológico en los primeros 5 años de vida. Rev Cub Hematol Inmunol Hemoter 1999;15:96–104.
14.
Altland K, Heredero L: Diagnóstico prenatal de la anemia a hematies falciformes. Rev Cub Ped 1974;46:237–244.
15.
Rodríguez L, Heredero L, López J, Fernández J, Oliva JA: Neural tube defects in Havana City: Incidence and prenatal diagnosis. Zentralbl Gynäkol 1982;104:1325–1327.
16.
Rodríguez L, Heredero L, Oliva JA, Zaldivar O: Prenatal diagnosis by measurement of alpha-fetoprotein in Havana City. Prenat Diagn 1987;7:657–661.
17.
Rodríguez L, Sánchez R, Hernández J, Carrillo L, Oliva JA, Heredero L: Results of 12 years’ combined maternal serum alpha-fetoprotein and ultrasound monitoring for prenatal detection of fetal malformations in Havana City, Cuba. Prenat Diagn 1997;17:301–304.
18.
Llanusa C, Sánchez R, Rodríguez L: Alpha-Fetoprotein Screening Program: Organizational aspects and psycho-social impact (Havana City). Rev Cub Med General Integral 1998;141:43–47 (online in English available in MEDICC Review: www.medicc.org).
19.
Vergel G, Sánchez R, Heredero L, Rodríguez L, Martínez A: Primary prevention of neural tube defects with folic acid supplementation: Cuban experience. Prenat Diagn1990;10:140–152.
20.
Casana M, Menéndez F, Quintana J, Quiñones O, Lavista M: Cytogenetic prenatal diagnosis. Experiences and results from May 1984 to January 1985. Rev Cub Ped 1986;58:745–752.
21.
Quintana J, Quiñones O, Méndez L, Lavista M, Gómez M, Dieppa N: Resultados del diagnóstico prenatal citogenético en las provincias occidentales de Cuba, 1984–1998. Rev Cub Genét Humana 1999;1:3 (or http://www. sigemec.sld.cu\rcgh\esp\revista_esp\rcgh_esp.htm).
22.
Quintana J: Clinical cytogenetics in Cuba. Eur Cytogenet Assoc Newslett 1999;4:23–24.
23.
Solis R, Heredero L, Carlos N, Quintana J, Casanave J, Días W, Martínez A, Orraca M, Becker D, Coto R, Estrada R, Rosquete R, Bencomo F, Barrios M, Rodríguez L, Fernández J: Detección sistemática de riesgo prenatal de cromosomopatías (Síndrome Down) mediante la evaluación combinada de HCG y AFP en suero materno y edad de la gestante. Internal publication Centro National de Genética Médica, Havana, 2001.
24.
Ferrero M, Lotti F, Cendán I, Pérez A: Tendencias del Síndrome Down en Cuba. Su relación con la edad materna y la tasa de fecundidad. Rev Cub Ped 1998;70:141–147.
25.
World Atlas of Birth Defects, ed 2. International Centre for Birth Defects of the International Clearinghouse for Birth Defects Monitoring Systems, Geneva, 2003.
26.
Heredero L, Atencio J, Vega E, Gutiérrez E, Damián A: Diagnóstico Precoz de Fenilcetonuria en Cuba (estudio preliminar). Rev Cub Ped 1986;58:1.
27.
Barrios B, Heredero L, Damiani A, Gutiérrez E, Cobet G, Machill G: Estudio de Hiperfenilalaninemias en el Occidente de Cuba. Rev Cub Ped 1989;61:99–106.
28.
Barrios B, Gutiérrez E, Cuadras Y, Damiani A: Programa Nacional de Prevención de Hiperfenilalaninemias en Cuba. III Jornada Provincial de Ciencias Básicas Médicas ‘Girón 2001’. Libro de resúmenes.
29.
Gutiérrez E, Barrios B, Taboada L: Valoración clínica, psicológica y de laboratorio a niños con hiperfenilalaninemia benigna al nacimiento. Rev Cub Ped 2002;74:4.
30.
Barrios B, Gutiérrez E: 4 años de Experiencia en el Diagnóstico de Errores Innatos del Metabolismo en Población con riesgo. III Jornada Provincial de Ciencias Médicas ‘Girón 2001’. Libro de resúmenes.
31.
Penchaszadeh VB, Heredero L, Punales-Morejón D, Rojas I, Pérez ET: Genetic counseling training in Cuba. Am J Hum Genet 1997;6(suppl A):1098.
32.
Anuario estadístico de salud 2000. Ministerio de Salud Publica de la Republica de Cuba. www.sld.cu/anuario/indice.html.
33.
Orozco G, Nodarse A, Cordovés M, Auburger G: Autosomal dominant cerebellar ataxia. Clinical analysis of 263 patients from a homogeneous population in Holguín, Cuba. Neurology 1990;40:1369–1375.
34.
Auburger G, Orozco G, Ferreira R, Gispert S, Paradoa M, Estrada M, García M, Farral M, Williamson R, Chamberlain S, Heredero L: Autosomal dominant ataxia: Genetic evidence for locus heterogeneity from a Cuban founder-effect population. Am J Hum Genet 1990;46:1163–1177.
35.
Gispert S, Twells R, Orozco G, Brice A, Weber J, Heredero L, Sceufler K, Riley B, Allotey R, Nothers C, Hillermann R, Lunkes A, Khati C, Stevanin G, Hernández A, Magariño C, Klockgether T, Durr A, Chneiweiss H, Enczmann J, Farral M, Beckmann J, Mullan M, Wernet P, Agid Y, Freund J, Williamson R, Auburger G, Chamberlain S: Chromosomal assignment of the second locus for autosomoal dominant cerebellar ataxia (SCA2) to chromosome 12q23–24.1. Nat Genet 1993;4:295–299.
36.
Pulst S, Nechiporuk A, Nechiporuc T, Sispert S, Xiao Ning C, Lopez I, Pearlman S, Starkman S, Orozco G, Lunkes A, DeJong P, Rouleau G, Auburger G, Korenberg J, Figueroa C, Sahba S: Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996;14:269–276.
37.
Paneque M, Santos N, Tamayo H, Reinaldo R, Velásquez L, Almagur L, Hechavarría R, Mourino T, Cruz T: Type 2 spinocerebellar ataxia: Acceptance of prenatal diagnosis in descendants at risk. Rev Neurol 2001;33:904–908.
38.
Collazo T, Magariño C, Chávez R, Suardíaz B, Gispert S, Gómez M, Rojo M, Heredero L: Frequency of Delta-F508 mutation and XV2C/KM19 haplotypes in Cuban cystic fibrosis families. Human Hered 1995;45:55–57.
39.
Lantigua A, Moras F, Arechaederra M, Rojas I, Morales E, Rodríguez H, Viñas C, Noa C, Barrios B: Etiological characterization of 512 severely mentally retarded institutionalized patients in Havana. Community Genet 1999;2:184–189.
40.
Lunkes A, Hartung U, Magariño C, Rodríguez M, Palmero A, Rodríguez L, Heredero L, Weisenbachu J, Weber J, Auburger G: Refinement of the OPA I locus on chromosome 3q28-q29 to a region of 2–8 cM, in one Cuban pedigree with autosomal dominant optic atrophy type Kjer. Am J Hum Genet 1993;57:968–970.
41.
Bertoli A, Marcheco B, Llibre J, Gómez N, Borrajero I, Severijen E, Joose M, van Duijn C, Heredero L, Heutink P: A novel presenilin 1 mutation (L174 M) in a large Cuban family with early onset Alzheimer disease. Neurogenetics 2002;4:97–104.
42.
Bertolí-Avella AM, Giroud-Benitez JL, Bonifati V, Álvarez-Gonzalez E, Heredero-Baute L, van Duijn CM, Heutink P: Suggestive linkage to chromosome 19 in a large Cuban family with late-onset Parkinson’s disease. Mov Disord DOI: 10.1002/mds.10534.
43.
Galjaard H: New names for old disciplines (review). J Inherit Metab Dis 2002;25:139–156.
© 2004 S. Karger AG, Basel
2004
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.